News
VYNE
0.6475
-0.12%
-0.0008
Weekly Report: what happened at VYNE last week (0622-0626)?
Weekly Report · 23h ago
Weekly Report: what happened at VYNE last week (0615-0619)?
Weekly Report · 06/22 09:00
Weekly Report: what happened at VYNE last week (0608-0612)?
Weekly Report · 06/15 09:00
These healthcare stocks are combining strong gains with reasonable prices
Seeking Alpha · 06/12 10:38
Weekly Report: what happened at VYNE last week (0601-0605)?
Weekly Report · 06/08 09:00
Vyne Therapeutics publishes investor presentation on Yarrow Bioscience, YB-101 anti-TSHR program for Graves' disease, thyroid eye disease
PUBT · 06/02 13:00
Weekly Report: what happened at VYNE last week (0525-0529)?
Weekly Report · 06/01 09:00
Weekly Report: what happened at VYNE last week (0518-0522)?
Weekly Report · 05/25 09:00
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline
TipRanks · 05/21 23:51
Vyne Therapeutics publishes Yarrow Bioscience investor presentation factsheet
PUBT · 05/21 21:05
Weekly Report: what happened at VYNE last week (0511-0515)?
Weekly Report · 05/18 09:00
Weekly Report: what happened at VYNE last week (0504-0508)?
Weekly Report · 05/11 09:00
Weekly Report: what happened at VYNE last week (0427-0501)?
Weekly Report · 05/04 09:00
Weekly Report: what happened at VYNE last week (0420-0424)?
Weekly Report · 04/27 09:00
Weekly Report: what happened at VYNE last week (0413-0417)?
Weekly Report · 04/20 09:00
Weekly Report: what happened at VYNE last week (0406-0410)?
Weekly Report · 04/13 09:00
Weekly Report: what happened at VYNE last week (0330-0403)?
Weekly Report · 04/06 09:00
Weekly Report: what happened at VYNE last week (0323-0327)?
Weekly Report · 03/30 09:00
Faron Pharmaceuticals appoints Heikki Jouttijärvi as CTO; late-stage development activities strengthen
Reuters · 03/26 07:20
Weekly Report: what happened at VYNE last week (0316-0320)?
Weekly Report · 03/23 09:00
More
Webull provides a variety of real-time VYNE stock news. You can receive the latest news about Vyne Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYNE
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.